Drug Trial Radar · NCT05999513
A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers
Last checked: Nov 19, 2026Latest source record: Oct 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Aug 21, 2023
Primary completion
Oct 31, 2023
Study completion Oct 31, 2023
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to compare the single-dose pharmacokinetics (PK) of casdatifan tablet versus the casdatifan capsule, and to evaluate the effect of food on the single-dose PK of casdatifan tablet in healthy adult volunteers.
Conditions
- Healthy Participants
Interventions
casdatifanDrug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Drug Concentration-Time Curve (AUC)Time frame: Predose, Up to 168 hours postdose
- Maximum Concentration (Cmax)Time frame: Predose, Up to 168 hours postdose
- Time to Maximum Concentration (Tmax)Time frame: Predose, Up to 168 hours postdose
- Terminal Half-Life Time (t1/2)Time frame: Predose, Up to 168 hours postdose
- Apparent Total Plasma Clearance (CL/F)Time frame: Predose, Up to 168 hours postdose
- Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F)Time frame: Predose, Up to 168 hours postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion, Inc.
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.